Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:56 AM
Ignite Modification Date:
2025-12-25 @ 3:56 AM
NCT ID:
NCT01490502
Eligibility Criteria:
Inclusion Criteria:
* Must meet Magnetic Resonance Imaging in MS (MAGNIMS) criteria for relapsing-remitting MS
* Age 18 to 50 years
* Expanded Disability Status Scale (EDSS) score ≤ 4.0
* MS disease duration ≤ 10 years if McDonald Relapse Remitting Multiple Sclerosis (RRMS;) ≤ 1 year if meets MAGNIMS RRMS criteria but not McDonald RRMS criteria
* If the patient meets the McDonald RRMS criteria (rather than McDonald Clinically
Isolated Syndrome (CIS) that is now classified as MAGNIMS MS):
* Must have had one clinical attack in past two years and at least one new silent T2 or gadolinium-enhancing lesion on brain MRI within the past year OR
* Must have had two clinical attacks in past two years, one of which occurred in the past year
* Females of child-bearing age must be willing to use at least one form of pregnancy prevention throughout the study.
* Must have had a 25-hydroxyvitamin D level of ≥ 15 ng/mL within past 30 days
* Must be willing to stop taking additional supplemental vitamin D, except as part of a multivitamin, and must be willing to not take cod liver oil.
Exclusion Criteria:
* Not be pregnant or nursing
* No ongoing renal or liver disease
* No known history of nephrolithiasis, hypercalcemia, sarcoidosis or other serious chronic illness including cancer (other than basal cell or squamous cell carcinoma of the skin), cardiac disease, or HIV.
* No ongoing hyperthyroidism or active infection with Mycobacterium species
* No known gastrointestinal disease (ulcerative colitis, Crohn's disease, celiac disease/gluten intolerance) or use of medications associated with malabsorption.
* No history of self-reported alcohol or substance abuse in past six months.
* No prior history of treatment with rituximab, any chemotherapeutic agent, or total lymphoid irradiation. No treatment in the past six months with natalizumab, fingolimod, or fumarate. If patient has received glatiramer acetate, they have not been exposed to more than three months of treatment. No treatment with other unapproved therapies for MS.
* No use of interferon beta or glatiramer acetate therapy for one month prior to screening
* No use of more than 1,000 IU vitamin D3 daily in the three months prior to screening
* No condition that would limit the likelihood of completing the MRI procedures
* No use of thiazide diuretics, digoxin, diltiazem, verapamil, cimetidine, heparin, low-molecular weight heparin, phenytoin, phenobarbital, carbamazepine, routine corticosteroids (eg scheduled monthly steroids, daily, etc), rifampin, or cholestyramine.
* No steroids within a month of screening.
* Not suicidal at screening visit (ineligible if answers "yes" to question 1 of screening Columbia Suicide Severity Rating Scale (C-SSRS) in PAST 2 MONTHS; or answers "yes" to questions 2-5 on C-SSRS for PAST 6 MONTHS; or answers "yes" to suicidal attempts or preparatory attempts in PAST 5 YEARS , http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225130.pdf).
* Serum calcium \>0.2 mg/dL above upper limit of normal.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
50 Years
Study:
NCT01490502
Study Brief:
Protocol Section:
NCT01490502